| |
Overall mortality
|
Breast cancer mortality
|
Recurrence
|
---|
Variable
|
Number
|
Events
|
HRa
|
95% CI
|
P-value
|
Events
|
HR
|
95% CI
|
P-value
|
Events
|
HR
|
95% CI
|
P-value
|
---|
Body mass index, k/m
2
| | | | | | | | | | | | | |
<18.5
|
66
|
11
|
1.08
|
0.59, 1.98
|
0.796
|
9
|
1.06
|
0.54, 2.06
|
0.864
|
12
|
0.88
|
0.49, 1.56
|
0.650
|
18.5 to 24.9
|
2,297
|
312
|
1.00
| | |
256
|
1.00
| | |
419
|
1.00
| | |
25.0 to 29.9
|
1,944
|
265
|
0.99
|
0.84, 1.16
|
0.880
|
220
|
1.00
|
0.83, 1.20
|
0.984
|
348
|
0.95
|
0.83, 1.10
|
0.522
|
30.0 to 34.9
|
945
|
139
|
1.07
|
0.87, 1.30
|
0.526
|
111
|
1.04
|
0.83, 1.29
|
0.757
|
173
|
0.98
|
0.82, 1.17
|
0.831
|
≥35.0
|
431
|
91
|
1.47
|
1.16, 1.85
|
0.001
|
68
|
1.32
|
1.01, 1.72
|
0.043
|
95
|
1.14
|
0.91, 1.42
|
0.249
|
| | | |
P for trend
|
0.002
| | |
P for trend
|
0.074
| | |
P for trend
|
0.287
|
Age at diagnosis, years
| | | | | | | | | | | | | |
23 to 44
|
1,667
|
276
|
1.00
| | |
245
|
1.00
| | |
416
|
1.00
| | |
45 to 54
|
2,036
|
228
|
0.66
|
0.55, 0.78
|
<0.001
|
187
|
0.61
|
0.50, 0.73
|
<0.001
|
296
|
0.54
|
0.47. 0.63
|
<0.001
|
55 to 64
|
1,443
|
202
|
0.92
|
0.77, 1.11
|
0.380
|
156
|
0.81
|
0.66, 0.99
|
0.036
|
231
|
0.66
|
0.56, 0.78
|
<0.001
|
65 to 76
|
537
|
112
|
1.41
|
1.13, 1.76
|
0.002
|
76
|
1.08
|
0.83, 1.39
|
0.583
|
104
|
0.81
|
0.65, 1.00
|
0.049
|
| | | |
P for trend
|
0.030
| | |
P for trend
|
0.655
| | |
P for trend
|
<0.001
|
Menopausal status
| | | | | | | | | | | | | |
Postmenopausal
|
2,661
|
421
|
1.00
| | |
322
|
1.00
| | |
461
|
1.00
| | |
Premenopausal
|
3022
|
397
|
0.75
|
0.66, 0.86
|
<0.001
|
342
|
0.85
|
0.73, 0.98
|
0.031
|
586
|
1.05
|
0.93, 1.19
|
0.415
|
Histology
| | | | | | | | | | | | | |
Ductal
|
4,809
|
700
|
1.00
| | |
571
|
1.00
| | |
892
|
1.00
| | |
Lobular
|
510
|
66
|
0.79
|
0.62, 1.02
|
0.072
|
52
|
0.76
|
0.57, 1.01
|
0.062
|
96
|
0.92
|
0.75, 1.14
|
0.446
|
Mixed
|
364
|
52
|
0.92
|
0.69, 1.22
|
0.561
|
41
|
0.89
|
0.65, 1.22
|
0.456
|
59
|
0.82
|
0.63, 1.07
|
0.150
|
Others
|
389
|
66
|
2.32
|
1.54, 3.49
|
<0.001
|
55
|
2.92
|
1.79, 4.75
|
<0.001
|
87
|
2.01
|
1.44, 2.83
|
0.000
|
Histological grade
| | | | | | | | | | | | | |
1
|
499
|
35
|
1.00
| | |
23
|
1.00
| | |
55
|
1.00
| | |
2
|
2,404
|
277
|
2.09
|
1.47, 2.97
|
<0.001
|
217
|
2.51
|
1.63, 3.87
|
<0.001
|
382
|
1.84
|
1.39, 2.45
|
<0.001
|
3
|
2,391
|
440
|
3.70
|
2.62, 5.23
|
<0.001
|
369
|
4.77
|
3.13, 7.28
|
<0.001
|
523
|
2.82
|
2.13, 3.72
|
<0.001
|
Unknown
|
389
|
66
|
2.32
|
1.54, 3.49
|
<0.001
|
55
|
2.92
|
1.79, 4.75
|
<0.001
|
87
|
2.01
|
1.44, 2.83
|
<0.001
|
Pathologic primary tumor size
| | | | | | | | | | | | | |
T1
|
2,794
|
249
|
1.00
| | |
194
|
1.00
| | |
349
|
1.00
| | |
T2
|
2,665
|
510
|
1.96
|
1.68, 2.28
|
<0.001
|
417
|
2.03
|
1.71, 2.41
|
<0.001
|
628
|
1.78
|
1.57, 2.04
|
<0.001
|
T3
|
224
|
59
|
2.14
|
1.61, 2.84
|
<0.001
|
53
|
2.39
|
1.76, 3.25
|
<0.001
|
70
|
1.98
|
1.53, 2.57
|
<0.001
|
| | | |
P for trend
|
<0.001
| | |
P for trend
|
<0.001
| | |
P for trend
|
<0.001
|
Estrogen receptor/progesterone receptor
| | | | | | | | | | | | | |
Both negative
|
1,502
|
300
|
1.00
| | |
256
|
1.00
| | |
349
|
1.00
| | |
Any of them positive
|
4,132
|
503
|
0.49
|
0.43, 0.57
|
<0.001
|
394
|
0.45
|
0.38, 0.53
|
<0.001
|
679
|
0.59
|
0.51, 0.67
|
<0.001
|
Unknown
|
49
|
15
|
0.77
|
0.46, 1.31
|
0.338
|
14
|
0.82
|
0.48, 1.41
|
0.471
|
19
|
1.00
|
0.63, 1.59
|
0.998
|
Human epidermal growth factor-2 status
| | | | | | | | | | | | | |
Negative
|
4,055
|
518
|
1.00
| | |
407
|
1.00
| | |
660
|
1.00
| | |
Positive
|
830
|
182
|
1.34
|
1.13, 1.59
|
0.001
|
153
|
1.42
|
1.18, 1.71
|
<0.001
|
223
|
1.38
|
1.18, 1.61
|
<0.001
|
Unknown
|
798
|
118
|
1.04
|
0.85, 1.28
|
0.690
|
104
|
1.17
|
0.94, 1 · 45
|
0.172
|
164
|
1.14
|
0.95, 1.36
|
0.157
|
Type of surgery
| | | | | | | | | | | | | |
Mastectomy
|
2,621
|
512
|
1.00
| | |
420
|
1.00
| | |
633
|
1.00
| | |
Conservative
|
3,062
|
306
|
0.71
|
0.61, 0.82
|
<0.001
|
244
|
0.71
|
0.60, 0.83
|
<0.001
|
414
|
0.73
|
0.65, 0.83
|
<0.001
|
Hormonotherapy
| | | | | | | | | | | | | |
No
|
1,439
|
314
|
1.00
| | |
263
|
1.00
| | |
354
|
1.00
| | |
Yes
|
4,045
|
451
|
0.42
|
0.36, 0.48
|
<0.001
|
356
|
0.39
|
0.33, 0.46
|
<0.001
|
622
|
0.51
|
0.45, 0.58
|
<0.001
|
Unknown
|
199
|
53
|
0.79
|
0.58, 1.06
|
0.112
|
45
|
0.77
|
0.56, 1.07
|
0.120
|
71
|
1.05
|
0.81, 1.37
|
0.692
|
Initial undertreatment (first dose <85%)
| | | | | | | | | | | | | |
No
|
5,532
|
648
|
1.00
| | | | | | | | | | |
Yes
|
151
|
16
|
1.01
|
0.78,1.31
|
0.932
|
16
|
1.06
|
0.64, 1.75
|
0.820
|
20
|
0.84
|
0.54, 1.31
|
0.447
|
Overall undertreatment (dose <85%)
| | | | | | | | | | | | | |
None
|
5,083
|
725
|
1.00
| | |
599
|
1.00
| | |
943
|
1.00
| | |
Epirubicine <85%
|
78
|
24
|
1.55
|
1.02, 2.36
|
0.040
|
20
|
1.56
|
0.98, 2.47
|
0.059
|
25
|
1.29
|
0.86, 1.93
|
0.226
|
Cyclophosphamide <85%
|
296
|
56
|
1.28
|
0.98, 1.69
|
0.074
|
41
|
1.13
|
0.82, 1.56
|
0.446
|
63
|
1.14
|
0.88, 1.47
|
0.323
|
Fluorouracil <85%
|
181
|
33
|
1.20
|
0.84, 1.70
|
0.316
|
23
|
1.01
|
0.66, 1.53
|
0.977
|
34
|
0.98
|
0.69, 1.38
|
0.888
|
Doxorubicin <85%
|
226
|
38
|
1.30
|
0.93, 1.81
|
0.119
|
27
|
1.12
|
0.76, 1.65
|
0.576
|
42
|
1.13
|
0.82, 1.54
|
0.451
|
Docetaxel <85%
|
176
|
32
|
1.08
|
0.74, 1.57
|
0.696
|
24
|
0.96
|
0.62, 1.47
|
0.846
|
39
|
1.04
|
0.74, 1.46
|
0.814
|
Paclitaxel <85%
|
244
|
27
|
1.43
|
0.94, 2.18
|
0.092
|
16
|
1.05
|
0.62, 1.78
|
0.863
|
30
|
1.09
|
0.74, 1.61
|
0.662
|
- aHazard ratio, 95% CI and P-value adjusted for study and treatment regimen.